

2nd World Congress on

ADVANCES IN ADDICTION SCIENCE AND MEDICINE

&
10th International Conference on

DEMENTIA AND DEMENTIA CARE

July 24-25, 2019 | Rome, Italy

Introducing “Precision Addiction Management (PAM®)” utilizing polymorphic matched algorithms and Pro-Dopamine regulation to combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) globally

Kenneth Blum^{*1,2}, Marjorie C Gondré-Lewis^{2,3,4}, David Baron^{1,2}, DO Lisa Lott², Jessica Ponce-Rodriguez², Mark Moran², Lyle Fried⁵, Mauro Ceccanti^{2,6}, Raju Hajela⁷, Rajendra D Badgaiyan^{2,8}

¹Western University Health Sciences Graduate School of Biomedical Sciences, USA

²Geneus Health, USA

³Howard University, USA

⁴Howard University College of Medicine, USA

⁵Transformational Treatment Center, USA

⁶University of Rome, Italy

⁷University of Calgary, USA

⁸Ichan School of Medicine at Mount Sinai, USA

Research into the neurogenetic basis of addiction identified and characterized by Reward Deficiency Syndrome (RDS) includes all drug and non-drug addictive, obsessive and compulsive behaviors. This keynote presents a new model for the prevention and treatment of RDS behaviors based on objective biologic evidence. Currently, research directed toward improving treatment for highly drug-dependent patients in underserved populations is the basis of an NIH grant awarded to Drs. Kenneth Blum and Marjorie Gondré-Lewis. The grant explores utilization of the Genetic Addiction Risk Score (GARS®) and the neuronutrient pro-dopamine regulator KB220. The development of GARS followed seminal research in 1990, whereby, Blum’s group identified the first genetic association with severe alcoholism. The non-invasive GARS test identifies and measures the total number of risk alleles of genes and catabolic enzymes affecting an individual’s neurochemical hypodopaminergic function and has been associated in hundreds of studies with RDS behaviors. In an unpublished study, the GARS predicted drug and alcohol severity predisposition as measured by the Addiction Severity Index (ASI) [≤ 4 alleles for Drug & ≤ 7 alleles for Alcohol]. Genotyping data on approximately 1000 subjects [addicted, chronic pain, opioid maintained and non-addicted] will be presented including Italian subjects. “Precision Addiction Management” (PBM®) uses the GARS to customize KB220PAM formulations to deliver putative dopamine homeostasis based on developed algorithms matched to polymorphic results. Presented evidence derived from animal and human studies using BOLD neuroimaging and behavioral methodologies, support homeostatic activation of brain dopamine in the reward circuitry by KB220PAM, as well as anti-substance seeking and modification of RDS behaviors. RDS encompasses behaviors like PTSD, ADHD, over-eating, shopping, hoarding and related RDS cognitive insults. Combating the drug crisis requires PBM across ethnic groups, to bring dopamine homeostasis to those born with RDS predisposition. It is the goal through this novel model that by using PBM the addiction field will have a synergistic tool along with MAT or even alone, to overcome dopamine dysregulation either surfeit (adolescents) or deficit (adults) by the induction of “dopamine homeostasis.